A phase-I open-label study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375) following a single oral dose in healthy male subjects

被引：0
|
作者：
Hibberd, M
Stevenson, SJ
机构：
[1] Takeda Europe Res & Dev Ctr Ltd, London, England
[2] Covance Clin Res Unit Ltd, Leeds, W Yorkshire, England
来源：
SLEEP | 2004年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
121
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [21] A phase I study to evaluate the short-term effects of ramelteon (TAK-375) on endocrine function in healthy adult subjects
    Tolbert, D
    Karim, A
    Demissie, S
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1210 - 1210
  • [22] The Absorption, Distribution, Metabolism, and Excretion of Binimetinib Following a Single Oral Dose of [14C]Binimetinib 45 mg in Healthy Male Participants
    Huynh, Dustin
    Hahn, Erik
    Reddy, Micaela B.
    Chavira, Renae
    Wollenberg, Lance
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2025, 13 (01):
  • [23] Absorption, Distribution, Metabolism and Excretion of [14C]Dexlansoprazole in Healthy Male Subjects
    Grabowski, Brian
    Lee, Ronald D.
    CLINICAL DRUG INVESTIGATION, 2012, 32 (05) : 319 - 332
  • [24] Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects
    Ogasawara, Ken
    Xu, Christine
    Kanamaluru, Vanaja
    Siebers, Nicholas
    Surapaneni, Sekhar
    Ridoux, Laurence
    Palmisano, Maria
    Krishna, Gopal
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 307 - 314
  • [25] Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects
    Ken Ogasawara
    Christine Xu
    Vanaja Kanamaluru
    Nicholas Siebers
    Sekhar Surapaneni
    Laurence Ridoux
    Maria Palmisano
    Gopal Krishna
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 307 - 314
  • [26] Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects
    Slatter, JG
    Stalker, DJ
    Feenstra, KL
    Welshman, IR
    Bruss, JB
    Sams, JP
    Johnson, MG
    Sanders, PE
    Hauer, MJ
    Fagerness, PE
    Stryd, RP
    Peng, GW
    Shobe, EM
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (08) : 1136 - 1145
  • [27] Investigation of the absorption, metabolism, excretion, and mass balance of [14C]-pacritinib in healthy subjects: a phase I study
    Al-Fayoumi, Suliman
    Amberg, Sherri
    Zhou, Huafeng
    Millard, Lindsey
    Singer, Jack W.
    Dean, James P.
    CANCER RESEARCH, 2016, 76
  • [28] A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [14C] Prucalopride After a Single Oral Dose in Healthy Volunteers
    Flach, Stephen
    Scarfe, Graeme
    Dragone, Jeffrey
    Ding, Jie
    Seymour, Mark
    Pennick, Mike
    Pankratz, Todd
    Troy, Steven
    Getsy, Jay
    CLINICAL THERAPEUTICS, 2016, 38 (09) : 2106 - 2115
  • [29] [14C]- DALCETRAPIB ADME FOLLOWING A SINGLE ORAL DOSE IN HEALTHY MALE SUBJECTS.
    Derks, M.
    Busse-Reid, R.
    Kuhlmann, O.
    Paehler, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S24 - S24
  • [30] A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects
    Acharya, Milin
    Gonzalez, Martha
    Mannens, Geert
    De Vries, Ronald
    Lopez, Christian
    Griffin, Thomas
    NamPhuong Tran
    XENOBIOTICA, 2013, 43 (04) : 379 - 389
12345